Loading content

Ms Catherine Angwin

MRC-ABPI Diabetes Stratification Project Manager

01392 408185

RILD Building 

I currently work with Professor Andrew Hattersley on the TriMaster clinical trial, a randomised double-blind three-way crossover trial of third-line diabetes therapies. This multicentre CTIMP is one strand of the MRC-funded MASTERMIND project led by University of Exeter, looking at stratification in Type 2 diabetes.  In addition, I manage the overall MASTERMIND project, providing support for the Strand 2 work in statistical analysis and health economic outcomes.

I joined the University of Exeter in 2010 as part of Professor Hattersley's diabetes research team and have worked in clinical trial, research and project management roles. 

Based in the NIHR Exeter Clinical Research Facility and Exeter Clinical Trials Unit, I've worked on clinical research projects in diabetes, including genetics of diabetes and stratification of Type 2. Previous studies include managing the MASTERMIND and RetroMASTER clinical studies, work with the Stroke Research Network as the coordinating centre for English-sites in the INTERSTROKE study and coordinating the EU FP7 CEED3 research project.

Qualifications

MSc International Development 

Research

Research interests

I work in the research area of stratification of Type 2 diabetes.

 

Research projects

  • MRC-ABPI Stratification and Extreme Response Mechanism IN Diabetes (MASTERMIND), including MASTERMIND and RetroMASTER clinical studies
  • Diabetes Research on Patient Stratification (DIRECT)
  • INTERSTROKE study - A study of the Importance of Conventional and Emerging Risk Factors of Stroke
  • Collaborative European Effort to Develop Diabetes Diagnostics (CEED3)

Key publications | Publications by category | Publications by year

Publications by category


Journal articles

Angwin C, Pearson E, Hattersley A (2016). Crossover studies can help the individualisation of care in type 2 diabetes: the MASTERMIND approach. Practical Diabetes, 33(4), 115-117. Full text.

Conferences

Jones AG, Angwin C, Hammersley S, Rogers L, Shields BM, Pearson ER, Hattersley AT (2016). The DPPIV inhibitor sitagliptin lowers postprandial glucose without improving postprandial insulin secretion: a MASTERMIND study.  Author URL.
Dennis JM, Hattersley AT, Weedon M, Angwin C, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Development of oedema is associated with an improved glycaemic response in patients initiating thiazolidinediones: a MASTERMIND study.  Author URL.  Full text.
Dennis JM, Hattersley AT, Weedon M, Angwin CD, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Patients who develop oedema on initiating thiazolidinedione therapy have an improved glycaemic response: a MASTERMIND study.  Author URL.  Full text.
Rodgers LR, Pearson ER, Hammersley S, Angwin CD, JMcDonald T, Shields BM, Hattersley AT, Jones AG, Consortium MASTERMIND (2015). Patients with a high fasting glucose respond better to sulphonylureas than dipeptidyl peptidase IV (DPP-IV) inhibitors: a MASTERMIND study.  Author URL.
Rodgers LR, Pearson ER, Angwin CD, Hammersley S, McDonald TJ, Shields BM, Hattersley AT, Jones AG, Consortium M (2015). Response to glucose lowering therapy can be assessed by a brief period of treatment withdrawal: a MASTERMIND study.  Author URL.

Publications by year


2016

Angwin C, Pearson E, Hattersley A (2016). Crossover studies can help the individualisation of care in type 2 diabetes: the MASTERMIND approach. Practical Diabetes, 33(4), 115-117. Full text.
Jones AG, Angwin C, Hammersley S, Rogers L, Shields BM, Pearson ER, Hattersley AT (2016). The DPPIV inhibitor sitagliptin lowers postprandial glucose without improving postprandial insulin secretion: a MASTERMIND study.  Author URL.

2015

Dennis JM, Hattersley AT, Weedon M, Angwin C, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Development of oedema is associated with an improved glycaemic response in patients initiating thiazolidinediones: a MASTERMIND study.  Author URL.  Full text.
Dennis JM, Hattersley AT, Weedon M, Angwin CD, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Patients who develop oedema on initiating thiazolidinedione therapy have an improved glycaemic response: a MASTERMIND study.  Author URL.  Full text.
Rodgers LR, Pearson ER, Hammersley S, Angwin CD, JMcDonald T, Shields BM, Hattersley AT, Jones AG, Consortium MASTERMIND (2015). Patients with a high fasting glucose respond better to sulphonylureas than dipeptidyl peptidase IV (DPP-IV) inhibitors: a MASTERMIND study.  Author URL.
Rodgers LR, Pearson ER, Angwin CD, Hammersley S, McDonald TJ, Shields BM, Hattersley AT, Jones AG, Consortium M (2015). Response to glucose lowering therapy can be assessed by a brief period of treatment withdrawal: a MASTERMIND study.  Author URL.

Back | Edit Profile